Special Issue "Cancer Drug Resistance"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 June 2014)
Dr. Xiaolong He
Department of Biopharmaceutical Sciences, College of Pharmacy and Cancer Center, University of Illinois at Chicago, Chicago, IL 60612, USA
Website | E-Mail
Interests: multidrug resistance; ABC transporters; tumorigenesis; targeted therapy; alternative splicing; cancer stem cells; gene targeting; biomarkers
Drug resistance represents a major obstacle to the success of cancer treatments. Drug resistance occurs not only with classical chemotherapeutics, but also with more recent, molecularly-targeted therapies. A variety of molecular mechanisms have been implicated in the development of resistance; these mechanisms include increased drug efflux, altered drug metabolism, mutated or amplified drug targets, enhanced compensatory signaling pathways, etc.
Modern technologies in genomics, proteomics, and epigenomics have made it possible to dissect the molecular changes underlying drug resistance in an unprecedentedly detailed and comprehensive manner. The current challenge is to identify clinically meaningful biomarkers from these “-omics” studies so as to predict individual patients' responses to particular drugs and devise drug combinations to overcome or prevent potential resistance. This Special Issue is devoted to publishing original research reports and review articles that concern drug resistance in cancer treatment. The topics can be, but are not limited to the following:
- High-throughput analysis of drug-sensitive and resistant human tumors
- Epigenetic changes in drug-resistant cancer cells
- microRNAs in the development of cancer drug resistance
- Biomarkers for prediction of drug response
- ABC transporters in drug resistance
- Tumor heterogeneity and drug resistance
- Treatment of resistant cancer cells
Dr. Xiaolong He
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer drug resistance
- targeted therapy
- ABC transporters
- high-throughput analysis